Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients.

ABSTRACT: EGFR-TKIs are effective therapies for non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, responses vary within individuals and resistant disease inevitably emerges. A prospective cohort of 130 patients with advanced EGFR mutation NSCLC were enrolled. Pre-and post-treatment plasma from subjects treated with EGFR-TKIs were obtained. The correlation between EGFR mutation abundance using the Idylla™ ctEGFR mutation assay, radiographic assessment, and clinical outcomes were analyzed. Eighty-nine patients with retrieved blood collection were analyzed. Undetectable ctEGFR (49.5%), detectable ctEGFR CqMut-high (23.5%), and detectable ctEGFR CqMut low (27%) using CqMut cutoff at 28.1, represented consecutive incremental tumor burden by radiographic assessment and o

SUBMITTER: Sitthideatphaiboon P 

PROVIDER: S-EPMC11696231 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature